Aurinia Pharmaceuticals Inc. (AUPH) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 11 Buy, 3 Hold.
The consensus price target is $15.50 (low: $15.00, high: $16.00), representing a downside of 3.5% from the current price $16.07.
Analysts estimate Earnings Per Share (EPS) of $0.03 and revenue of $0.24B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.04 vs est $0.03 (beat +53.8%). 2025: actual $2.14 vs est $0.78 (beat +173.8%). Analyst accuracy: 51%.
AUPH Stock — 12-Month Price Forecast
$15.50
▼ -3.55% Downside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Aurinia Pharmaceuticals Inc., the average price target is $15.50, with a high forecast of $16.00, and a low forecast of $15.00.
The average price target represents a -3.55% change from the last price of $16.07.
Highest Price Target
$16.00
Average Price Target
$15.50
Lowest Price Target
$15.00
AUPH Analyst Ratings
Buy
Based on 14 analysts giving stock ratings to Aurinia Pharmaceuticals Inc. in the past 3 months
EPS Estimates — AUPH
51%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.04
vs Est $0.03
▲ 35.0% off
2025
Actual $2.14
vs Est $0.78
▲ 63.5% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is improving.
Revenue Estimates — AUPH
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.235B
vs Est $0.236B
▼ 0.2% off
2025
Actual $0.283B
vs Est $0.281B
▲ 0.9% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
